On the HCPLive Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.
July 6th 2023
An analysis of data from nearly 750,000 adolescents from more than 40 countries offers insight into the changing, and possibly inaccurate, perceptions of healthy body weight among younger people since the turn of the century.
Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.
Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.
To celebrate the 10-year anniversary of the AMA recognizing obesity as a disease, this feature leverages the perspective of key opinion leaders to examine what has changed and what has not since the AMA's declaration in June 2013.
A matched case-control study of nearly 100 women details the reduced effect of anti-obesity medications in those with a history of breast cancer and aromatase inhibitor use.
A prospective, nonrandomized trial has returned results indicating adolescents and young adults who undergo bariatric surgery experienced a decrease in bone density relative to their counterparts who opted for exercise and nutrition counseling.
Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.
An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.
An analysis of data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program provides an overview of changing rates of access and utilization of metabolic and bariatric surgery among US youths.
Phase 2 data suggest the oral small-molecule GLP-1R agonist reduced HbA1c at all dose levels studied and reduced body weight at doses of ≥80 mg twice daily compared with placebo in adults with T2D.
Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.
Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.
Most associate bariatric surgery with improved health outcomes, but a new study suggests clinicians and patients should be aware of potential changes in bone density brought on as a result of undergoing bariatric surgery.
A retrospective, propensity score-matched analysis details significant risk reductions achieved with bariatric surgery in patients with nonalcoholic fatty liver disease and obesity.
A systematic review and meta-analysis of more than 120 randomized trials offers new insight into the effects of weight regain on cardiometabolic risk up to 5 years after the cessation of a behavioral management program.